anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a hair cosmetic having high ultraviolet ray absorbing effect on hair and excellent in long acting property of the effect by blending a specific quaternary ammonium salt with a higher alcohol and a ultraviolet absorbent liquid at ordinary temperature at a specific ratio. CONSTITUTION:This hair cosmetic is obtained by blending (A) a quaternary ammonium salt expressed by the formula (R) is a 14-22C alkyl or OH; R2 to R4 each is a 1-3C alkyl, OH or benzyl; X is a halogen or a 1-2C alkylsulfate group) with (B) a higher alcohol having a 14-22C straight-chain alkyl group and (C) a ultraviolet absorbent liquid at ordinary temperature. In this blend, the component A is used in an mount of 0.1-5.0wt.% based on total amount of hair cosmetic and a molar ratio of the component B to the component A is 3-15 and the component C is used in an amount of >=0.01wt.% based on total amount of hair cosmetic. The quaternary ammonium salt of the component A includes e.g. trimethylammonium chloride. The higher alcohol of the component B includes e.g. cetyl alcohol. The ultraviolet absorbent of the component C includes e.g. homomentyl salicylate.
Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease that resists therapy targeting androgen signaling, the primary driver of prostate cancer. mCRPC resists androgen receptor (AR) inhibitors by amplifying AR signaling or by evolving into therapy-resistant subtypes that do not depend on AR. Elucidation of the epigenetic underpinnings of these subtypes could provide important insights into the drivers of therapy resistance. In this study, we produced chromatin accessibility maps linked to the binding of lineage-specific transcription factors (TF) by performing assay for transposase-accessible chromatin sequencing on 70 mCRPC tissue biopsies integrated with transcriptome and whole-genome sequencing. mCRPC had a distinct global chromatin accessibility profile linked to AR function. Analysis of TF occupancy across accessible chromatin revealed 203 TFs associated with mCRPC subtypes. Notably, ZNF263 was identified as a putative prostate cancer TF with a significant impact on gene activity in the double-negative subtype (AR- neuroendocrine-), potentially activating MYC targets. Overall, this analysis of chromatin accessibility in mCRPC provides valuable insights into epigenetic changes that occur during progression to mCRPC. Significance: Integration of a large cohort of transcriptome, whole-genome, and ATAC sequencing characterizes the chromatin accessibility changes in advanced prostate cancer and identifies therapy-resistant prostate cancer subtype-specific transcription factors that modulate oncogenic programs.
The present invention relates to a traditional Chinese prescription medicine for treating chronic hepatitis B and its prepn. method. It is prepd. from 10 traditional Chinese medicinal herbs including bupleurum root, astragalus root, fructus ligustri lucidi, poria cocos, red sage root, rhizoma polygoni cuspidati, licorice etc. and is processed into dissolvable granule prepn. mixture or oral liquor. Its advantages include: easily available raw material, precise in curative effect, no recur, no toxic side effect, low in cost etc.
Compsns. for treating sexual frigidity or impotence contain an opiate antagonist (I), which is administered in a dose of 1-20 mg. (I) is pref. naloxone, naltrexone or nalorphine. The compsns. are pref. administered orally or intravenously. The compsns. are esp. useful for normalising sexual capacity in subjects whose capacity has been reduced by opiate-type narcotics or analgesics (including beta-endorphins, enkephalins and their enzyme-resistant analogues) but they can also be used to treat loss of capacity due to natural causes.
We included severe ED patients that underwent radical prostatectomy at least one year previously and failed to respond to PDE5i therapy, who scored 0-2 on the rigidity scale (RS) during PDE5i therapy. Treatment included 2 sessions/week for 3 weeks, repeated after a 3-week no-treatment interval. At each session LI-ESWT was applied on the penile shaft and crus for 3 minutes in 5 different penile anatomical sites (intensity of 0.09 mj/mm2, 300 shocks/site). One-month after end of treatment the same baseline assessment was repeated. An active PDE5i medication regime was then provided and final erectile function was reassessed. Main endpoints for success were changes in RS and in the International Index of Erectile Function (IIEF-ED) Domain score. This study further emphasises the need to study specific populations with unique etiologies causing ED.
The Hem-o-lok Weck clip is part of a polymer locking ligation system often employed for hemostasis in surgical practices. Its use is routine in a wide array of surgical subspecialties. Surgeons have limited options in removing these clips when they are aberrantly positioned. Herein, we describe a novel, cost-effective approach for removing a Hem-o-lok clip using standard robotic instruments. This simple approach will allow surgeons to remove a Hem-o-lok clip precisely and quickly if it is not adequately placed. During a routine robotic-assisted laparoscopic prostatectomy a Hem-o-lok Weck clip was noted to be in juxtaposition to the rectal wall, and it was deemed appropriate to remove it. Ultimately, the indwelling Prograsp forceps was moved from the right fourth arm position to the left arm position. This allowed the Prograsp forceps to compress the scissors in the right hand port, which was insufficient in cutting the hinge of the clip. This provided sufficient force to cut through the clip at its hinge with ease. The Hem-o-lok Weck clip is used in various surgical specialties. It is occasionally placed suboptimally and requires removal. Given the challenge of finding and using the clip removal device, surgeons should be aware of this simple and cost-effective way of removing a Hem-o-lok clip if desired.
PURPOSE:To enhance the fragrance of a perfume composition and, in particular, lift up the fruity scent by incorporating a small amount of nonanenitrile into a perfume composition. CONSTITUTION:A small amount of nonanenitrile is incorporated into a perfume composition comprising, e.g. a compound perfume like a flower oil, such as a rose or jasmine oil, or a fruity compound perfume, such as a flora fruity or oriental fruity compound perfume. This can render the scent of a flower-oil- like compound perfume like a natural fragrance, lift up the fruity scent of a fruity compound perfume or fruity type compound perfume, and impart good body and a high-grade feeling. The amount of nonanenitrile to be incorporated varies depending upon the types of compound perfume prepared and the purposes; however, the suitable amount is 0.0001-10wt.% based on the whole composition. Nonanenitrile is a known substance used as, e.g. an intermediate for producing drugs.
Histiocytic disorders mostly occur as de-novo nodal or extranodal benign masses with rare secondary malignant transformation. A 10-year-old female presented with 10-cm cervical swelling since 9 months associated with fever. Computed tomography revealed left cervical lymphadenopathy and bilateral lung nodules. Lymph node excision biopsy showed effacement of architecture by atypical histiocytes with marked nuclear pleomorphism and frequent mitosis. Focal areas showed mature histiocytes with emperipolesis. The cells were immunopositive for CD68, CD163, and S100 (focal), whereas they were negative for Langerin and CD1a. The Ki67 proliferative index was 30%. A diagnosis of histiocytic sarcoma in a background of Rosai-Dorfman disease was made.
G-CSF IC on days 0, 1, 7, 8, 14, 15, 21 and 22. Bortezomib IV on days 1, 8, 15 and 22. Cyclophosphamide CIV on days 1, 8, 15 and 22. Dexamethasone IV on days 1, 2, 8, 9, 15, 16, 22 and 23.
The intervention will consist of a 16-week, home-based gait/balance training and progressive resistance exercises for lower extremities using resistance power bands. Participants will be given the home-based gait/balance training and progressive resistance exercise training access via a link or by DVD, and the resistance training band, and wide, firm foam surface. The intervention group will begin with light warm-up and stretching activity then a 10 minute each of gait/balance and 10 minutes of resistive (strength) training components. The program begins with light stretching to address any range of motion limitations that may affect ability to maintain balance and postural stability, and consisted of hamstring quadricep, gastroc, and soleus stretches. During stretching exercises, participants held each stretch for 10-15 seconds, repeating each stretch 2-3 times for each lower extremity. Stretching exercises do not change during the intervention.
The invention provides a processing method of a liquor angelica slice for promoting coronary circulation. The angelica without wiping off root and skin is undertaken the procedures of purifying, rinsing, soaking, cutting into thin slices, drying or baking. A certain amount of rice wine is added for mixing, oppressing, stir-frying and cooling. Compared with raw angelica, the liquor angelica slice processed in the method has obvious effect of inhibiting uterine smooth muscle contraction and anti-platelet aggregation and anti-pain effect. The invention can be used as a recipe for Chinese medicine, or finished medicine and natural medicine, as well as an ingredient for health products such as health food and cosmetics of special purpose. The processing method is simple and easy for quality control and industrial production. The application of the method provides a standardized procedure for the processing of traditional Chinese angelica.
A mounting body of research points to cerebrovascular dysfunction as a fundamental element in the pathophysiology of Parkinson's disease (PD). In the current feasibility study, blood-oxygen-level-dependent (BOLD) MRI was used to measure cerebrovascular reactivity (CVR) in response to hypercapnia in 26 PD patients and 16 healthy controls (HC), and aimed to find a multivariate pattern specific to PD. Whole-brain maps of CVR amplitude (i.e., magnitude of response to CO2) and latency (i.e., time to reach maximum amplitude) were computed, which were further analyzed using scaled sub-profile model principal component analysis (SSM-PCA) with leave-one-out cross-validation. A meaningful pattern based on CVR latency was identified, which was named the PD CVR pattern (PD-CVRP). This pattern was characterized by relatively increased latency in basal ganglia, sensorimotor cortex, supplementary motor area, thalamus and visual cortex, as well as decreased latency in the cerebral white matter, relative to HC. There were no significant associations with clinical measures, though sample size may have limited our ability to detect significant associations. In summary, the PD-CVRP highlights the importance of cerebrovascular dysfunction in PD, and may be a potential biomarker for future clinical research and practice.
The present invention relates to a raditional Chinese medicine composition for treating chloasma, which takes more than 10 traditional Chinese medicines of radix rehmanniae preparata, glossy privet fruit, yerbadetajo herb, barbary wolfberry fruit etc. as the raw materials. The present invention has the effects of nourishing water, nourishing yin, nourishing blood and moistening skin. Based on the differential treatment of the traditional Chinese medicine, the invention is developed by combining the latest scientific research results with the traditional Chinese medicine. The present invention aims at providing the traditional Chinese medicine composition for treating chloasma. The present invention is characterized by accurate efficacy, safety, convenience, no toxicity or side effects and low price.
The incidence, hospitalization rate, and mortality associated with pneumonia are significant, contributing to a substantial disease burden. Post-discharge follow-up and intervention strategies for pneumonia patients are often insufficient, leaving patients vulnerable to readmission or mortality due to recurrent pneumonia and related complications. In clinical practice, there is a predominant focus on the amelioration of clinical symptoms during hospitalization, with limited attention to ongoing outpatient interventions aimed at reducing readmission rates. Consequently, there is a pressing need for cohort studies on pneumonia.

This study is a multicenter, prospective cohort study involving adult patients discharged after pneumonia treatment. Approximately 5,000 patients will be enrolled, with follow-up assessments conducted every three months over the course of one year. After one year, patients will be stratified into two cohorts based on the duration of Traditional Chinese medicine (TCM) treatment received (e.g., continuous treatment for two months or intermittent treatment for three months per year). One cohort will consist of patients receiving TCM, while the other will include those who did not receive TCM. The primary endpoint is the rate of hospital readmission, while secondary outcomes include treatment satisfaction, physician-reported outcomes, patient-reported outcomes, quality of life, nutritional status, incidence of acute upper respiratory tract infections, and survival. This study aims to evaluate the clinical efficacy and safety of TCM in the management of adult pneumonia patients following discharge.
The present invention relates to a method of ex vivo amplification of neonatal T cells from umbilical cord blood which comprises obtaining light density mononuclear cells from a sample of umbilical cord blood and then culturing said light density mononuclear cells in a serum-deprived culture medium supplemented with various cytokine combinations. Particularly, there are reported the effects exerted by cytokine combinations including stem cell factor (SCF), interleukin-7, interleukin-4 and interleukin-2, on the amplification of T cells from cord blood mononuclear cells cultured for 10-11 days under serum-deprived conditions. Of all the combinations investigated, SCF plus interleukin-7 sustained the best fold increase (FI) of total nucleated cells (FI=6.4~1.17), amplifying preferentially CD4+ over CD8+ T cell subsets (FI=4.72~0.79 vs 2.73~1.2, respectively, p<0.05). The addition of interleukin-2 to this combination did not significantly increase the total number of cells generated (FI=7.4~2.27) but allowed preferential amplification of CD8+  over CD4+ T cells (FI=6.04~0.14 vs 1.67~0.6, respectively, p<0.05). Single strand conformation polymorphism analysis of the T-cell receptor V.beta.-chain rearrangements expressed by the expanded T cells indicated that the complexity of the T-cell repertoire had increased after 10 days of culture in the presence of SCF and IL-7. Interestingly, a modest expansion (FI=8.67~1.5) of myeloid progenitor cells was also observed in these cultures. These results indicate that it is possible, by modulating the cytokines added to the cultures, to expand specific T cell subsets for adoptive immunotherapy without lousing myeloid progenitor cells necessary for neutrophil recovery after cord blood transplantation.
Patients receive standard consolidation therapy, standard interim maintenance therapy, and standard DI therapy as in group 1, arm I, followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
The needs of the rapidly expanding population of adults growing older with intellectual and developmental disabilities (IDD) and their families span both the IDD and the aging service systems. The use of Project ECHO (Extension for Community Healthcare Outcomes) for professional education can bridge gaps and span boundaries between them at the macro, meso, and micro levels. A series of 10 ECHO sessions over 12 months was developed, incorporating key content on IDD and AD/ADRD for 145 providers in over 20 agencies. Impacts were assessed by a follow-up survey sent to participants after each program. The evaluation included quantitative assessment of ECHO features and a retrospective pre- and posttest of knowledge acquisition; a separate item assessed intention to apply information. Qualitative data were collected from open-ended items. The case presentation and discussion were the most effective ECHO components. Knowledge acquisition was significant for all sessions; most important uses included providing better care to clients/patients, training staff, and educating family and/or caregivers. Participants were aligned with two distinct groups, one with a predominant knowledge focus, the other with an emphasis on networking. Project ECHO can bridge gaps and span boundaries between the IDD and aging care systems at multiple levels, improving interprofessional collaboration and care by addressing both knowledge and networking needs of providers.
In recent decades, hyaluronic acid (HA) has attracted great attention as a new treatment option for osteoarthritis. Classical therapies are not able to stop the cartilage degeneration process nor do they favor tissue repair. Nowadays, it is accepted that high molecular weight HA can reduce inflammation by promoting tissue regeneration; therefore, the aim of this study was to verify the efficacy of a new high molecular weight HA of plant origin (called GreenIuronic®) in maintaining joint homeostasis and preventing the harmful processes of osteoarthritis. Methods: The bioavailability of GreenIuronic® was investigated in a 3D intestinal barrier model that mimics human oral intake while excluding damage to the intestinal barrier. Furthermore, the chemical significance and bio-logical properties of GreenIuronic® were investigated, even in conditions that simulate osteoarthritis. Results: Our data demonstrated that GreenIuronic® crosses the intestinal barrier without side effects as it has a chemical-biological profile, which could be responsible for many specific chondrocyte functions. Furthermore, in the osteoarthritis model, GreenIuronic® can modulate the molecular mechanism responsible for preventing and restoring the degradation of cartilage. Conclusion: According to our results, this new form of HA appears to be well absorbed and distributed to chondrocytes, preserving their biological activities. Therefore, the oral administration of GreenIuronic® in humans can be considered a valid strategy to obtain beneficial therapeutic effects during osteoarthritis.
Adsorption-based extracorporeal therapies have been subject to technical developments and clinical application for close to five decades. More recently, new technological developments in membrane and sorbent manipulation have made it possible to deliver more biocompatible extracorporeal adsorption therapies to patients with a variety of conditions. There are several key rationales based on physicochemical principles and clinical considerations that justify the application and investigation of such therapies as evidenced by multiple ex vivo, experimental and clinical observations. Accordingly, unspecific adsorptive extracorporeal therapies have now been applied to the treatment of a wide array of conditions from poisoning to drug overdoses, to inflammatory states and sepsis, and acute or chronic liver and kidney failure. In response to the rapidly expanding knowledge base and increased clinical evidence, we convened an Acute Disease Quality Initiative consensus conference dedicated to such treatment. The data show that hemoadsorption has clinically acceptable short-term biocompatibility and safety, technical feasibility and experimental demonstration of specified target molecule removal. Pilot studies demonstrate potentially beneficial effects on physiology and larger studies of endotoxin-based hemoadsorption have identified possible target phenotypes for larger randomized controlled trials. Moreover, in a variety of endogenous and exogenous intoxications, removal of target molecules has been confirmed in vivo. However, some studies have raised concerns about harm, or failed to deliver benefits. Thus, despite many achievements, modern hemoadsorption remains a novel and experimental intervention with limited data, and a large research agenda.
PROBLEM TO BE SOLVED: To produce a powder compsn. capable of improving the dispersibility of particulate powder with high productivity in a short time. SOLUTION: A 1st base material made of particulate powder of 0.005 to <0.1μm average primary particle diameter is mixed with a 2nd base material made of inorg. powder of 0.5-100μm average primary particle diameter, a surface treating agent and a solvent so as to regulate the weight ratio between the 1st and 2nd base materials to 3:7 to 8:2. The resutlant mixture is put in a medium stirring mill packed with beads of 0.2-2mm average diameter and it is wet- disintegrated by means of the mill to produce the objective powder compsn. Particulate titanium oxide or zinc oxide is preferable as the 1st base material, a flaky inorg. pigment such as talc, mica, sericite or kaolin is preferable as the 2nd base material and siloxane such as methylhydrogenpolysiloxane or alkylsilane such as decyltrimethoxysilane is preferable as the surface treating agent.
Participants will undergo a cryoablation procedure with the Galil Medical Cryoablation System according to the manufacturer's guidelines. Participant preparation, anesthesia, intra-operative monitoring, and postoperative management for the study cryoablation procedure will be identical to those for standard cryoablation treatment routinely performed at the clinical centers that participated in this study and will be at the discretion of the Investigators. No more than 3 tumors in 1 lung can be treated in a single session, and no more than 5 total lung tumors (across both lungs) can be treated during the study.
PURPOSE: To obtain cosmetic, containing a natural-born chitosan plenty in quantity, available in a low price and having a molecular weight in a constant range, and having good preservation characteristics. CONSTITUTION: The cosmetic includes a chitosan having 3,000-700,000, preferably 120,000-450,000 molecular weight. The cosmetic has advantages because a natural-born product plenty in quantity and available in a low price is used as a preservative. The using amount of the chitosan can be smaller. The chitosan is used for a product having no resistance adjacent microorganisms. The cosmetic can be preserved both in an aseptic medium (an aseptic and airtight vessel) and in not aseptic medium (a not airtight vessel or an opened vessel) for a long period. The chitosan is obtained by performing a deacetylation of a chitin with an alkali. The deacetylation degree is preferably 70-95%. The cosmetic preferably includes 50-5,000μg/g of the chitosan.  The chitosan is formulated in the cosmetic by dispersing the chitosan in water, performing a ultrasonic treatment of the dispersed liquid, subjecting the treated liquid to centrifugation, freeze-drying the liquid after the centrifugation to form a powder and formulating the obtained powder into the cosmetic.